



Access this article online

Quick Response Code:



Website:

<https://turkjemergmed.com/>

DOI:

10.4103/tjem.tjem_198_23

Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review

Mehmet Muzaffer Islam*, Merve Osoydan Satici, Serkan Emre Eroglu

Department of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey

*Corresponding author

Submitted: 04-09-2023

Revised: 06-12-2023

Accepted: 07-12-2023

Published: 08-01-2024

ORCID:

MMI: 0000-0001-6928-2307

MOS: 0000-0002-3169-0724

SEE: 0000-0002-3183-3713

Address for
correspondence:

Dr. Mehmet Muzaffer

Islam,

Department of Emergency

Medicine, University

of Health Sciences,

Umraniye Training and

Research Hospital,

Elmalikent District Adem

Yavuz Street No: 1,

Istanbul, Turkey.

E-mail: mehm

etislam1988@gmail.com

Abstract:

In the field of critical care medicine, substantial research efforts have focused on identifying high-risk patient groups. This research has led to the development of diverse diagnostic tools, ranging from basic biomarkers to complex indexes and predictive algorithms that integrate multiple methods. Given the ever-evolving landscape of medicine, driven by rapid advancements, changing treatment strategies, and emerging diseases, the development and validation of diagnostic tools remains an ongoing and dynamic process. Specific changes in complete blood count components, such as neutrophils, lymphocytes, monocytes, and platelets, are key immune system responses influenced by various factors and crucial in systemic inflammation, injury, and stress. It has been reported that indices such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and delta neutrophil index calculated using various ratios of these elements, are important predictors of various outcomes in conditions where the inflammatory process is at the forefront. In this narrative review, we concluded that NLR, PLR, SII, and SIRI show promise in predicting outcomes for different health conditions related to inflammation. While these tests are accessible, reliable, and cost-effective, their standalone predictive performance for a specific condition is limited.

Keywords:

Delta neutrophil index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune inflammation index, systemic inflammation response index

Introduction

Within the medical literature, identifying high-risk patient groups within

critically ill populations, such as cancer, sepsis, polytrauma, acute ischemic stroke, and acute coronary syndrome, has been a

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Islam MM, Satici MO, Eroglu SE. Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turk J Emerg Med 2024;24:8-19.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

notable research emphasis. To fulfill this goal, a variety of diagnostic tools have been developed over time. These tools vary in complexity, ranging from straightforward biomarkers based on single measurements to more intricate indexes that consider ratios, as well as sophisticated prediction models and algorithms that integrate multiple methods.

The literature regarding diagnostic accuracy is well-rounded and exhibits a dynamic nature. Due to rapid developments in the field of medicine, changes in treatment approaches, and the growing significance of newly emerging diseases or conditions, the process of developing new diagnostic tools or validating the existing ones remains ongoing.

The concept of the neutrophil-to-lymphocyte ratio (NLR), initially proposed by Zahorec in 2001, stands as a noteworthy outcome of these efforts.^[1] Just like the shock index, this new parameter, which is formulated by the ratio of two simple complete blood count parameters, has been found to provide better results in the prognosis of many critical conditions than its components, thus laying the foundation of a fairly extensive literature.

In this comprehensive narrative review, our objective was to cover the literature on four widely studied parameters-NLR, platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and delta neutrophil index (DNI) while highlighting pivotal points and significant insights.

Neutrophil-to-lymphocyte Ratio

Neutrophilia and lymphocytopenia, which are immune system responses to systemic inflammation, injury, and stress, are influenced by various factors.^[2] Neutrophils serve as precursors to the innate immune response, engaging in phagocytosis and releasing cytokines and mediators.^[3] They act as the main effectors in the early hyperdynamic phase of infection and contribute to adaptive immunity regulation.^[4] Conditions such as infection, acute stroke, myocardial infarction, atherosclerosis, severe trauma, burns, major surgery, and any situation involving tissue damage activating SIRS can lead to increased neutrophil counts.^[5]

Neutrophilia during systemic inflammation occurs due to neutrophil demargination, suppressed neutrophil apoptosis, and stem cell stimulation through growth factors such as G-CSF.^[6,7] Endocrine stress responses marked by elevated serum cortisol and catecholamines, or triggered by sympathetic activation, can also raise neutrophil count.^[8,9]

Lymphocytopenia, a notable decrease in circulating lymphocyte count, is described after malignancy, severe trauma, major surgery, severe sepsis, and systemic inflammation.^[2,8,10] This decrease in lymphocytes, indicative of depressed cell-mediated immunity, has been extensively studied. For instance, in cases such as multiple trauma and major surgery, neuroendocrine stress and tissue injury alter the T4/T8 lymphocyte ratio, causing lymphocytopenia within 6 h, lasting 2–7 days.^[8,11] The mechanisms responsible for lymphopenia also involve margination and redistribution of lymphocytes within the lymphatic system, along with increased apoptosis through tumor-related cytokines (particularly interleukin [IL-10] and tumor necrosis factor beta).^[6,12] Moreover, factors such as ischemia-reperfusion injury (e.g., myocardial infarction) and upregulated pro-inflammatory cytokines (e.g., acute pancreatitis) contribute to lymphocytopenia.

Simultaneous yet opposite changes in neutrophil and lymphocyte counts reflect a multifactorial dynamic response, influenced by immunologic, neuroendocrine, humoral, and biological factors, adding a layer of complexity and interest to this phenomenon.^[6] In addition, the early change (<6 h) in neutrophil and lymphocyte counts following acute physiological stress endows them as earlier markers compared to other laboratory parameters (e.g., white blood cell count and C-reactive protein [CRP]).

Although the separate role of neutrophil and lymphocyte counts in the clinical severity of systemic inflammatory response has been previously examined, the neutrophil-lymphocyte ratio (NLR) was identified by Zahorec in 2001.^[1,10,11] NLR, the ratio of neutrophil and lymphocyte counts (in absolute and/or relative % values), has been proposed as a simple, reliable, and cost-effective severity parameter of various stressful events (peritonitis, abdominal sepsis, complicated postsurgical period, severe sepsis, and septic shock) in critically ill patients. In subsequent research, it has been reported that the NLR is more reliable in predicting patient survival compared to neutrophil or lymphocyte counts alone.^[11,13]

When examining the reported normal values of NLR in healthy adults of diverse races worldwide, the median NLR appears to be 1.65 (range 1.2–2.15).^[9] While NLR values below 5 are considered normal in the original study, distinct cutoff values have been reported for different diseases (e.g., malignancy, sepsis, and cardiovascular diseases), and there remains a lack of consensus on a unified pathological value in this regard.

Recognizing the link between cancer-related systemic inflammation and elevated NLR levels, numerous studies

have explored the prognostic value of NLR in various solid tumors, especially in gastrointestinal malignancy.^[14-23] In a large-scale analysis of 40,559 patients, Templeton *et al.* demonstrated that an NLR greater than 4 independently predicts diminished overall survival in multiple tumors (hazard ratio [HR] = 1.81; 95% confidence interval [CI] = 1.67–1.97).^[24] However, the majority of meta-analyses identify an NLR cutoff value above 3.0 (interquartile range = 2.5–5.0) as a credible index for assessing the prognosis of a variety of solid tumors including colorectal, gastric, esophageal, pancreatic, liver, urological, and gynecological cancers.^[9,19-21] NLR not only holds independent prognostic relevance for overall, cancer-free, and cancer-specific survival, but also proves valuable in monitoring various oncological therapies, and stratification of cancer as it correlates with tumor size, tumor stage, metastatic potential, and lymphatic invasion.^[21,22,25-28]

NLR has been well recognized as a convenient marker for the diagnosis of bacteremia and sepsis. Its sensitivity in the diagnosis of bacteremia, infection, and sepsis has been validated in numerous studies.^[29-32] A recent meta-analysis of 11,564 patients with sepsis indicated that a higher NLR was independently associated with poor clinical prognosis in patients with sepsis (mean HR = 1.75; 95% CI = 1.56–1.97). NLR was significantly higher in nonsurvivors than in survivors (mean HR = 1.18; 95% CI = 0.42–1.94).^[33] The majority of the existing studies indicate that NLR ≥ 5 serves as a valid indicator of sepsis, while values above 10 are considered significant in septic shock.^[34,35] It has also been suggested that not only high NLR values but also lower-than-expected NLR values (0.1–0.7) are associated with 28-day mortality.^[36] While it has been suggested that NLR is more accurate and cost-effective than CRP as a marker of sepsis, its superiority over procalcitonin has not been established.^[31,34,37] NLR also has good diagnostic accuracy in neonatal sepsis (area under the curve [AUC] = 0.87; 95% CI = 0.84–0.89).^[38]

The relationship between NLR and pneumonia/respiratory failure has been extensively researched in the literature. NLR has shown a strong predictive utility in terms of short- and long-term mortality, ICU admission, and rehospitalization in community-acquired pneumonia.^[39-41] Furthermore, NLR stands as the most extensively investigated biomarker in COVID-19 pneumonia due to the remarkable impact of SARS-CoV-2 infection on the immune system and its complex effects.^[42] NLR is an independent prognostic marker for stratifying disease severity and mortality in patients with COVID-19. The majority of the existing systematic reviews or meta-analyses show a higher NLR ratio (≥ 5 –7) on admission predicts both severity

and mortality in COVID-19 patients.^[8,43,44] According to a recent comprehensive analysis, using an NLR cutoff value of ≥ 6.5 accurately predicted mortality with a high rate (AUC = 0.90; 95% CI 0.87–0.92), and using a cutoff of ≥ 4.5 was effective in determining the severity of the disease (AUC = 0.85; 95% CI 0.81–0.88).^[45] Beyond initial NLR, dynamic changes during hospitalization matter as increasing NLR during the clinical course links to severity and poor outcomes in COVID-19.^[46,47] There was a 10% increase in the risk of in-hospital mortality per unit increase in NLR (OR = 1.10; 95% CI = 1.05–1.14).^[44] Considering these findings, it is clear that NLR holds better diagnostic value than other hematological indices and biochemical markers, in the case of COVID-19. However, it remains evident that NLR alone cannot replace comprehensive scoring systems in clinical assessment.

NLR's predictive role in cardiovascular events is supported by various studies. Shah *et al.* established NLR >4.5 as an independent predictor of long-term coronary heart disease mortality in healthy populations.^[48] A large meta-analysis involving over 16,000 patients determined that high NLR on admission was associated with higher overall mortality both in patients with STEMI and NSTEMI (OR = 4.60; 95% CI: 2.84–7.45, and OR = 6.41; 95% CI: 2.65–15.50, respectively) compared to low NLR. A higher MACE risk was observed in STEMI patients with high initial NLR (OR = 3.71; 95% CI: 2.67–5.17).^[49] Recently, NLR also was found to be an independent predictor of short- and long-term adverse outcomes in acute heart failure.^[50] In conclusion, evidence highlights the promising role of NLR in enhancing diagnosis and prognosis prediction in various cardiac pathologies, particularly when combined with cardiac markers and scoring systems.

The association between high NLR and increased risk of venous thromboembolism (VTE) in patients with malignancy has been recognized (HR = 1.2; 95% CI = 1.0–1.4), and it has recently been shown that NLR is associated with an increased risk of VTE (including pulmonary embolism [PE], deep vein thrombosis [DVT], and cerebral venous thrombosis [CVT] in non-cancer patients and can predict recurrence but may not be sufficient to distinguish the subtypes.^[51,52] A meta-analysis of 2023 also revealed that NLR has a moderate prognostic value in the diagnosis of DVT in non-cancer patients (AUC = 0.74; 95% CI = 0.70–0.78), even though the cutoff values vary across the different studies.^[53]

Among the subjects studied it was found that in patients with diabetes mellitus, NLR independently predicted major adverse cardiac events (MACEs).^[54] Notably, NLR showed a significant increase in cases

of gestational diabetes.^[55] Furthermore, in patients with type 2 diabetes mellitus, NLR independently predicted poor glycemic control (OR: 1.809; 95% CI = 1.459–2.401).^[56]

Considering these findings, NLR serves as an accessible, cost-effective, and strong prognostic marker, for disease stratification and severity assessment in various stressful events, especially malignancy, sepsis, and COVID-19 forefront. While definitive threshold values are lacking, NLR, when combined with reliable infection/inflammation biomarkers, plays a pivotal role in guiding decision-making and disease management. Future research can further clarify its optimal ranges and enhance its diagnostic utility.

Platelet-to-lymphocyte Ratio

Both thrombocytosis and lymphocytopenia are linked to the extent of systemic inflammation, while the ratio of the platelet to lymphocyte count introduces a fresh marker that integrates both hematologic parameters. Especially in conditions that are potent triggers of systemic inflammatory response such as sepsis, malignancy, rheumatologic disorders, and trauma, in addition to the previously mentioned neutrophilia and lymphopenia, platelet proliferation is induced by pro-inflammatory cytokines (particularly IL-6 and IL-1).^[57,58] Thrombocytosis is linked to heightened inflammatory responses due to alterations in the body's microcirculation, augmented blood vessel permeability, platelet activation, and aggregation of a substantial number of platelets. Consequently, this exacerbates the overall inflammatory reaction within the body.

Platelets interact with tumor cells directly and contribute to tumor growth, invasion, and angiogenesis.^[59] High platelet counts are associated with poor prognosis in colorectal, gastric, esophageal, and pancreatic cancers.^[60,61] However, as an index, PLR was initially defined by Smith *et al.* in 2008.^[62] While individual preoperative CA19-9 and PLR (cut-off value: 150) had low specificities (72% and 73%, respectively) for periaampullary pancreatic tumor resectability, their combined model increased specificity to 96%. Furthermore, another study conducted by Smith *et al.* identified high PLR as an independent prognostic factor in pancreatic cancer, suggesting that PLR might serve as a superior prognostic marker compared to individual parameters or the NLR.^[63]

However, the abundance of controversial data that does not support the original study is also noteworthy.^[64-66] In a large-scale study with 27,031 cancer patients, high PLR value was revealed as a predictor of decreased

overall survival, regardless of age, gender, and tumor site (AUC = 0.632; 95% CI = 0.620–0.644). However, it was not deemed superior to other systemic inflammation-based prognostic scores.^[67] In a similar meta-analysis, it is concluded that a high PLR is independently associated with poorer overall survival across various solid tumors, and it is also not superior to other hematological indices (e.g., NLR, GPS).^[68] In fact, subsequent studies indicated that even in pancreatic cancer, where PLR originally emerged, NLR demonstrated better performance in predicting prognosis.^[69]

A large meta-analysis to investigate the prognostic role of PLR in various cancers indicated that elevated PLR significantly predicted poor overall survival (HR = 1.60; 95% CI = 1.35–1.90).^[70] The relevant literature from the past 6 years suggests that the mean AUC value for PLR in predicting poor outcome in colorectal cancer was 0.648, with a cutoff of 146.98, alongside sensitivity of 67.83% and specificity of 60.65%, while NLR shows better diagnostic accuracy (AUC = 0.74 with a cutoff = 3.31, sensitivity = 63.03%, and specificity = 62.55%).^[71] In conclusion, PLR is independently related to prognosis in many cancers, such as colorectal cancer, breast cancer, gastric cancer hepatocellular carcinoma, NSCLC, and SCLC.^[72-77] Although the relationship between PLR and malignancy has been mostly investigated in the literature, the unpartially elucidated mechanism, varying diagnostic accuracy across ethnicities, and uncertainty in the cutoff values raise questions about the diagnostic utility of PLR in terms of malignancy.

Atherosclerosis, the primary cause of coronary artery disease (CAD), arises from an immune-inflammatory response. Activated platelets initiate thrombus formation on the rupture of atherosclerotic plaques or endothelial cell erosion, fostering atherothrombotic disease.^[78] Consequently, platelet activation assumes a pivotal role in CAD and ACS.^[79] Therefore, the predictive role of PLR in cardiovascular events is supported by various studies. In a recent analysis comprising a total of 6,627 acute coronary syndrome patients, it was revealed that an elevated PLR (>150) leads to a twofold increase in the risk of in-hospital all-cause mortality and cardiovascular mortality (pooled RR = 2.15; 95% CI = 1.73–2.67 and RR = 1.95; 95% CI = 1.30–2.91, respectively), as supported by similar studies.^[80,81] In addition, studies have indicated a correlation between PLR and increased overall mortality in patients with NSTEMI.^[82] Furthermore, a study demonstrated that elevated PLR is associated with the recurrence of myocardial infarction, stroke, and subsequent heart failure.^[83] Considering these findings, an elevated PLR indicates the presence of inflammation, atherosclerosis, and coronary artery disease, and also serves as a prognostic indicator in cases of ACS.

Given the ease of calculating PLR and its widespread accessibility, further investigation is necessary to ascertain its diagnostic utility.

Multiple studies have demonstrated that elevated PLR values are associated with the presence and severity of rheumatologic diseases, particularly RA, SLE, and AS.^[84] While the majority suggested the combination of PLR with NLR as a potentially valuable approach for the precise assessment of inflammatory activity in rheumatologic diseases.^[80,85] Monitoring PLR and hematological indices hold the potential to aid in the follow-up of long-term anti-inflammatory and immunosuppressive therapies for rheumatic diseases. PLR also has been reported to predict the prognosis of sepsis, COVID-19, acute exacerbation of COPD, and PE.^[86-90] However, its prognostic significance was not as successful as compared to NLR.

In conclusion, PLR is closely associated with systemic inflammation and is a promising biomarker not only in rheumatologic diseases but also in ACS, COVID-19, and various respiratory diseases. However, the challenges associated with determining the optimal cutoff range, coupled with the predominantly retrospective design of many studies, present significant concerns. More longitudinal studies are warranted to establish its diagnostic performance, alone or in combination with other parameters, in clinical practice.

Systemic Immune-inflammation Index

Another widely mentioned biomarker in the current literature is the SII which was initially defined by Hu *et al.* in 2014 and is calculated through the following formula: " $SII = Platelet \times Neutrophil / Lymphocyte$ ".^[91] The notion of the potential utility of this index is rooted in the special relationship between these cells, where neutrophils, lymphocytes, and platelets play pivotal roles in numerous inflammatory processes. It was originally developed for prognostication of patients with hepatocellular carcinoma after curative resection. Even though it exhibited poor predictive performance in overall survival (AUC = 0.680, 95% CI = 0.59–0.77), SII elicited a significant impact in the academic literature.

The systemic immune inflammation index has predominantly revolved around the examination of outcomes related to malignancy. In addition, a multitude of meta-analyses exploring prognostications for numerous cancer subtypes can be found in the existing literature. Researchers have examined specific groups of different types of cancers in various meta-analyses, revealing that SII emerged as a useful marker for overall survival, progression-free survival, and responsiveness to immunotherapy among cancer patients in general.

A 2022 meta-analysis by Tian *et al.* comprising 14 articles and 2721 patients found that elevated SII levels (>750) indicate poor overall survival and progression-free survival (HR = 2.40; 95% CI = 2.04–2.82 and HR = 1.57; 95% CI = 1.33–1.86, respectively) in cancer patients who are medicated with immune checkpoint inhibitors.^[92] Another meta-analysis consisting of 15 studies and 2438 patients examined the prognosis and responsiveness of cancer patients to immunotherapy and indicated that higher SII levels are associated with poor overall survival, objective response rate, and progression-free survival (HR = 2.33; 95% CI = 2.02–2.69, HR = 0.73; 95% CI = 0.56–0.94, and HR = 0.56; 95% CI = 0.35–0.88, respectively).^[93]

Several meta-analyses examining the predictive value of SII report similar results in gynecological cancers, breast cancers, ovarian cancer, prostate cancer, renal cell carcinoma, small-cell lung cancer, gastric cancer, biliary tract cancer, pancreatic carcinoma, and nasopharyngeal carcinoma with an HR of overall survival ranging between 1.32 and 2.71.^[93-102] Conversely, SII was not found to be a significant predictor of progression-free survival in small-cell lung cancer, gastric cancer, and renal cell carcinoma in the same studies.^[97,98,102]

One of the best diagnostic performances of SII in malignancy-related outcomes appears to be testicular cancer. A very recent 2023 meta-analysis by Salazar-Valdivia *et al.* comprising 6 studies with a total of 833 patients reported that elevated SII levels indicate poor overall survival and progression-free survival (HR = 3.28; 95% CI = 1.3–8.9 and HR = 3.9; 95% CI = 2.53–6.02, respectively).^[103] Although the authors summarized the significance of SII in many outcomes, they did not discuss why SII might have performed better in testicular cancer.

The diagnostic performance of the SII in cardiovascular diseases, in general, was also examined extensively. The idea behind the hypothesis of this subject is the increase of neutrophil count in endothelial dysfunction and the active role of neutrophils with platelets in the formation of atherosclerosis.^[104,105] Moreover, some lymphocyte subtypes regulate inflammation and negatively affect the formation of atherosclerosis.^[106]

A 2022 meta-analysis by Ye *et al.* including 13 studies and 152,996 patients reported that elevated SII levels indicate an increased risk of future cardiovascular diseases such as ischemic stroke, hemorrhagic stroke, and myocardial infarction (HR = 1.31; 95% CI = 1.06–1.63, HR = 1.22; 95% CI = 1.10–1.37, and HR = 1.11; 95% CI = 1.01–1.23, respectively).^[107] In addition, studies are reporting that SII can be used as a predictor of severity in coronary artery disease and acute ischemic stroke.^[108,109] Huang

et al. published a meta-analysis in 2022 with a fairly large cohort of 18,609 patients with ischemic stroke and reported that elevated SII predicts poor outcomes such as mortality and hemorrhagic transformation (HR = 2.16; 95% CI = 1.75–2.67, HR = 2.09; 95% CI = 1.61–2.71, respectively).^[110] A pooled cutoff value could not be provided due to the increased heterogeneity between the studies.

The active participation of blood cells, especially neutrophils, and lymphocytes, in infectious processes implies that the SII could potentially serve as a significant biomarker for these outcomes as well. Nevertheless, a considerable number of subjects lacked meta-analyses due to the relatively lower volume of studies focusing on infective outcomes compared to other areas. A recent meta-analysis by Mangoni and Zinellu was published in 2023 and consisted of 40 studies that examine the utility of SII in predicting the disease severity, morbidity, and mortality in patients with COVID-19. In this study, the pooled sensitivity, specificity, and area under the curve of SII in predicting severe disease or mortality was reported to be 71% (95% CI = 67–75), 71% (95% CI = 64–77), and 0.770 (95% CI = 0.730–0.800).^[111] In this study, the authors indicated that even though SII had a significant association with some inflammation markers (albumin and lactate dehydrogenase), no other significant association was observed in terms of inflammation markers or other known risk factors for mortality of COVID-19, meaning that SII may carry valuable information about the degree of inflammation to a potential model.

A retrospective study conducted using a large cohort of MIMIC-IV benchmark dataset with 16,007 patients with sepsis reported that SII and 28-day mortality have a J-shaped relationship (HR = 1.40; 95% CI = 1.23–1.58 for the highest quartile of SII value). In this study, the lowest risk of 28-day mortality was at the SII levels of $774.46 \times 10^9/L$.^[112]

A prospective study with 345 patients examined the utility of SII in predicting the 28-day mortality of patients with community-acquired pneumonia and reported that the area under the curve of SII was 0.737 (95% CI = 0.672–0.802).^[113] However, it is noteworthy to point out that the outcome variable of the study is 28-day all-cause mortality and not in-hospital mortality or disease severity, which can be counted as a confounding limitation.

There are limited studies on other infections or inflammation-related outcomes. In a retrospective study with 513 patients with pancreatitis, the high SII group ($>755 \times 10^9/L$) had a significantly higher rate of 30-day all-cause mortality (HR = 2.57; 95%

CI = 1.35–4.88).^[114] The study did not examine the utility of SII in predicting severe acute pancreatitis or in-hospital mortality.

In conclusion, while the SII exhibited significant differences between the groups across nearly all the assessed outcome measures, its utility as a standalone test proved limited. Nonetheless, it can be inferred that SII holds significance as a biomarker due to its capacity to contribute substantial information to predictive models without inducing overfitting, especially in conditions related to malignancy. This is attributed to the consistency of its significance in numerous studies, and the fact that it is unaffected by confounding factors.

Systemic Inflammation Response Index

SIRI is an inflammatory biomarker identified in 2016 by Qi *et al.*, which is calculated according to the following formula; “ $SIRI = Neutrophil \times Monocyte / Lymphocyte$.”^[115] In the original study, the SIRI was developed to identify the candidates for aggressive chemotherapy in patients with pancreatic adenocarcinoma. The idea behind the identification of this biomarker was the hypothesis that these components may have a significant impact on survival in the malignant process, which consists of immunological and inflammatory components. Numerous studies have indicated that the prognostic significance of various cancer types, including pancreatic cancer, can be assessed through parameters such as white blood cell counts consisting of neutrophils, lymphocytes, and monocytes, alongside acute-phase proteins such as C-reactive protein.^[116–119] Although SIRI has been defined to be used as a prognostic marker in patients with malignancy, its diagnostic performance has been investigated in many diseases where inflammation is at the forefront.

The role of SIRI in the prognostication of malignant diseases is well-studied. All of the systematic reviews and meta-analyses about SIRI are about the diagnostic performance of the biomarker in some kind of malignancy.^[120–124] In a 2021 metaanalysis that investigates the prognostic performance of SIRI in cancer patients in general which includes 10,754 cancer patients, elevated SIRI was found to be associated with short overall survival with no significant heterogeneity (HR = 2.04; 95% CI = 1.82–2.29).^[120] Majority of the existing systematic reviews or meta-analyses showed similar results.^[121–123]

Although SIRI has been defined to be used as a prognostic marker in patients with malignancy, its diagnostic performance has also been investigated in many diseases where inflammation is at the forefront. For example, a 2021 study investigating the diagnostic performance of SIRI in identifying ischemic stroke patients, found

SIRI was an independent predictor of 90-day all-cause mortality, even though its predictive performance was not excellent (AUC = 0.622; 95% CI = 0.598–0.645).^[125] Another study in 2022 reported that SIRI was an independent predictor of poor functional outcome in ischemic stroke patients with a moderate predictive performance (AUC = 0.714; 95% CI: 0.658–0.765).^[126]

A large cohort study published in 2023 which examines the performance of SIRI for all-cause death and cardiovascular mortality in 42,875 patients (patients without acute coronary syndrome) found that patients with elevated SIRI are significantly under risk of cardiovascular or all-cause death (HR = 1.39; 95% CI = 1.14–1.68 and HR = 1.39; 95% CI, 1.26–1.52, respectively).^[127] Another recent study of 2023 investigating the performance of SIRI in patients with acute myocardial infarction with 4291 patients reported that SIRI was also an independent predictor of 30- and 90-day mortality with poor performance (AUC = 0.620, AUC = 0.624, respectively).^[128] Another study examining the performance of SIRI in identifying acute coronary syndrome patients at high risk of a MACE also found that SIRI was an independent predictor of MACE with poor performance (AUC = 0.624).^[129]

There is no extensive research about the role of SIRI in pancreatitis or cholecystitis but some very recent studies are being published. In the study of Biyik *et al.* with 332 patients with pancreatitis, SIRI was able to significantly predict severe acute pancreatitis and acute kidney injury (AUC = 0.782; 95% CI = 0.699–0.865, AUC = 0.776; 95% CI = 0.715–0.837, respectively).^[130]

Based on the existing literature, it can be said that SIRI is a promising biomarker of prognostication in patients with a condition of inflammatory-dominant pathophysiology. Given its status as a relatively recent biomarker, further studies are required to achieve a more precise assessment of its diagnostic significance in cases of infectious conditions. According to the available literature, predictive performance of SIRI limits this biomarker to be used as a standalone diagnostic tool.

Delta Neutrophil Index

In the early stages of an infectious process, when the neutrophil migration to the site of infection is limited by the over-production of cytokines and chemokines, the body responds by neutrophil proliferation resulting in immature granulocytes circulating through the peripheral bloodstream.^[131] Nigro *et al.* tested the prognostic performance of the immature granulocyte count in neonatal sepsis in 2005 and found it to have poor predictive power.^[132] Moreover, the calculation of

the immature granulocyte count was time-consuming and also showed variance depending on the observers' experience. Until 2008, the immature granulocyte count did not attract great attention. In 2008, Nahm *et al.* defined an index using immature granulocyte count; DNI.^[133] DNI can be defined as the fraction of immature granulocytes amongst the myeloperoxidase-positive cells and is automatically calculated using blood cell analyzers.^[134] The formula for the DNI is usually referred to as "DN = (the leukocyte subfraction assayed in the MPO channel by cytochemical reaction)–(the leukocyte subfraction counted in the nuclear lobularity channel by the reflected light beam)."^[133]

There still is not extensive literature on the predictive performance of the DNI in diverse outcomes. One of the first meta-analyses and systematic reviews on DNI by Park *et al.* investigated the diagnostic and prognostic power of DNI in 2017.^[135] One of the striking findings of this study is that the researchers found 12 eligible studies investigating 499 patients and 9549 control cases, which are carried out in a single center. In this study, the pooled sensitivity of the DNI for infection was found to be 67% (95% CI = 62–71), and specificity 94% (95% CI = 94–95). In the same study, the pooled sensitivity of the DNI for predicting mortality in the infected patients was found to be 70% (95% CI = 56–81) and specificity 78% (95% CI = 73–83). The authors concluded that DNI can be used as a diagnostic or prognostic tool for infectious outcomes, not as a standalone test but with other parameters such as procalcitonin.

Another meta-analysis and systematic review on DNI was published in 2018 by Ahn *et al.* investigates the value of the DNI in predicting mortality in patients with sepsis.^[131] The pooled AUC, sensitivity, and specificity of DNI in predicting mortality were found to be 0.820, 70% (95% CI = 60–80), and 72% (95% CI = 68–75), respectively. The authors concluded that the DNI is more valuable in septic conditions than leukocyte count and may be a useful tool to predict sepsis severity.

We could not find any additional meta-analyses or systematic reviews in the literature that investigated the utility of DNI; the majority of the available studies were clinical in nature. Most of the studies examined the usefulness of the DNI to predict various outcomes in patients with inflammation-related diseases such as cholecystitis, pancreatitis, abscess, and Fournier's Gangrene, demonstrating similar results.^[136–140] Nevertheless, given that these studies typically have a single-center focus and involve a limited number of patients, it is important to replicate these findings in diverse settings to obtain a definitive conclusion.

Conclusion

Our thorough review summarized a substantial amount of literature demonstrating significant predictive capabilities of NLR, PLR, SII, SIRI, and DNI across various inflammation-related clinical conditions and different outcomes. These parameters emerge as readily available, reproducible, and cost-effective metrics. Yet a common characteristic among these biomarkers is their limited standalone predictive performance for any given condition. Additional studies focusing on infectious processes may be warranted to obtain more precise insights about these indexes, especially about SII and SIRI. Nevertheless, these indexes offer pivotal insights by combining information from multiple variables into a single entity. This unified representation retains the essence of its components, effectively reducing the risk of overfitting in potential predictive models and aiding clinicians in making critical decisions.

Author contributions

Conceptualization: Mehmet Muzaffer İslam, Merve Osoydan Satıcı, Serkan Emre Eroğlu.

Methodology and literature review: Mehmet Muzaffer İslam, Merve Osoydan Satıcı.

Writing - original draft: Mehmet Muzaffer İslam, Merve Osoydan Satıcı, Serkan Emre Eroğlu.

Writing - review and editing: Mehmet Muzaffer İslam, Merve Osoydan Satıcı, Serkan Emre Eroğlu.

Visualization: Mehmet Muzaffer İslam.

Supervision: Mehmet Muzaffer İslam.

Project administration: Mehmet Muzaffer İslam.

Software: None.

Funding acquisition: None.

Resources: None.

Conflicts of interest

None Declared.

Funding

None.

References

- Zahorec R. Ratio of neutrophil to lymphocyte counts – Rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy* 2001;102:5-14.
- O'Mahony JB, Palder SB, Wood JJ, McIrvine A, Rodrick ML, Demling RH, et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. *J Trauma* 1984;24:869-75.
- Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on neutrophil function in severe inflammation. *Front Immunol* 2018;9:2171.
- Li Y, Wang W, Yang F, Xu Y, Feng C, Zhao Y. The regulatory roles of neutrophils in adaptive immunity. *Cell Commun Signal* 2019;17:147.
- Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases. *Int J Mol Sci* 2022;23:3636.
- Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. *Nat Rev Dis Primers* 2016;2:16045.
- Mahidhara R, Billiar TR. Apoptosis in sepsis. *Crit Care Med* 2000;28:N105-13.
- Dionigi R, Dominioni L, Benevento A, Giudice G, Cuffari S, Bordone N, et al. Effects of surgical trauma of laparoscopic versus open cholecystectomy. *Hepatogastroenterology* 1994;41:471-6.
- Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. *Bratisl Lek Listy* 2021;122:474-88.
- Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. *Am J Respir Crit Care Med* 1999;159:857-63.
- Menges T, Engel J, Welters J, Wagner RM, Little S, Ruwoldt R, et al. Changes in blood lymphocyte populations after multiple trauma: Association with posttraumatic complications. *Crit Care Med* 1999;27:733-40.
- Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. Differential induction of apoptosis in lymphoid tissues during sepsis: Variation in onset, frequency, and the nature of the mediators. *Blood* 1996;87:4261-75.
- Kumarasamy C, Sabarimurugan S, Madurantakam RM, Lakhotiya K, Samiappan S, Baxi S, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. *Medicine (Baltimore)* 2019;98:e14834.
- Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860-7.
- McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. *Br J Surg* 2003;90:215-9.
- Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. *Carcinogenesis* 2009;30:1073-81.
- Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell* 2011;144:646-74.
- Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. *Br J Cancer* 2013;108:901-7.
- Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. *Crit Rev Oncol Hematol* 2013;88:218-30.
- Bowen RC, Little NA, Harmer JR, Ma J, Mirabelli LG, Roller KD, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: A systematic review and meta-analysis. *Oncotarget* 2017;8:32171-89.
- Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Sci Rep* 2019;9:19673.
- Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med* 2020;18:360.
- Ohno Y, Nakashima J, Otori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. *J Urol* 2010;184:873-8.

24. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, *et al.* Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. *J Natl Cancer Inst* 2014;106:dju124.
25. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, *et al.* Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer* 2018;6:74.
26. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, *et al.* Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. *Br J Cancer* 2015;112:1904-10.
27. Zhang S, Qiu C, Yu H, Xu Y, Xu X. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. *Front Oncol* 2023;13:1070019.
28. Pinato DJ, Stavraka C, Flynn MJ, Forster MD, O'Cathail SM, Seckl MJ, *et al.* An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. *PLoS One* 2014;9:e83279.
29. Riché F, Gayat E, Barthélémy R, Le Dorze M, Matéo J, Payen D. Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock. *Crit Care* 2015;19:439.
30. Saliccioli JD, Marshall DC, Pimentel MA, Santos MD, Pollard T, Celi LA, *et al.* The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: An observational cohort study. *Crit Care* 2015;19:13.
31. Marik PE, Stephenson E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. *J Crit Care* 2020;60:135-9.
32. Ham SY, Yoon HJ, Nam SB, Yun BH, Eum D, Shin CS. Prognostic value of neutrophil/lymphocyte ratio and mean platelet volume/platelet ratio for 1-year mortality in critically ill patients. *Sci Rep* 2020;10:21513.
33. Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. *Am J Emerg Med* 2020;38:641-7.
34. Gürol G, Çiftçi İH, Terizi HA, Atasoy AR, Ozbek A, Köroğlu M. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? *J Microbiol Biotechnol* 2015;25:521-5.
35. Drăgoescu AN, Pădureanu V, Stănculescu AD, Chiutiu LC, Tomescu P, Geomăneanu C, *et al.* Neutrophil to lymphocyte ratio (NLR)-a useful tool for the prognosis of sepsis in the ICU. *Biomedicines* 2021;10:75.
36. Hwang SY, Shin TG, Jo IJ, Jeon K, Suh GY, Lee TR, *et al.* Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patients. *Am J Emerg Med* 2017;35:234-9.
37. Rehman FU, Khan A, Aziz A, Iqbal M, Mahmood SB, Ali N. Neutrophils to lymphocyte ratio: Earliest and efficacious markers of sepsis. *Cureus* 2020;12:e10851.
38. Xin Y, Shao Y, Mu W, Li H, Zhou Y, Wang C. Accuracy of the neutrophil-to-lymphocyte ratio for the diagnosis of neonatal sepsis: A systematic review and meta-analysis. *BMJ Open* 2022;12:e060391.
39. Lee H, Kim I, Kang BH, Um SJ. Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. *PLoS One* 2021;16:e0250067.
40. Kuikel S, Pathak N, Poudel S, Thapa S, Bhattarai SL, Chaudhary G, *et al.* Neutrophil-lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. *Health Sci Rep* 2022;5:e630.
41. Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, *et al.* Neutrophil-to-lymphocyte ratio: An emerging marker predicting prognosis in elderly adults with community-acquired pneumonia. *J Am Geriatr Soc* 2017;65:1796-801.
42. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, *et al.* Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020;71:762-8.
43. Sarkar PG, Pant P, Kumar J, Kumar A. Does neutrophil-to-lymphocyte ratio at admission predict severity and mortality in COVID-19 patients? A systematic review and meta-analysis. *Indian J Crit Care Med* 2022;26:361-75.
44. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, *et al.* Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect* 2020;81:e6-12.
45. Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, *et al.* Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis. *Crit Care* 2020;24:647.
46. Zeng ZY, Feng SD, Chen GP, Wu JN. Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: A prospective cohort study. *BMC Infect Dis* 2021;21:80.
47. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb Res* 2020;192:3-8.
48. Shah N, Parikh V, Patel N, Patel N, Badheka A, Deshmukh A, *et al.* Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the national health and nutrition examination survey-III. *Int J Cardiol* 2014;171:390-7.
49. Dentali F, Nigro O, Squizzato A, Gianni M, Zuretti F, Grandi AM, *et al.* Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature. *Int J Cardiol* 2018;266:31-7.
50. Davison BA, Takagi K, Edwards C, Adams KF Jr., Butler J, Collins SP, *et al.* Neutrophil-to-lymphocyte ratio and outcomes in patients admitted for acute heart failure (as seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF studies). *Am J Cardiol* 2022;180:72-80.
51. Grilz E, Posch F, Königsbrügge O, Schwarzwinger I, Lang IM, Marosi C, *et al.* Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. *Thromb Haemost* 2018;118:1875-84.
52. Ding J, Yue X, Tian X, Liao Z, Meng R, Zou M. Association between inflammatory biomarkers and venous thromboembolism: A systematic review and meta-analysis. *Thromb J* 2023;21:82.
53. Hu J, Cai Z, Zhou Y. The association of neutrophil-lymphocyte ratio with venous thromboembolism: A systematic review and meta-analysis. *Clin Appl Thromb Hemost* 2022;28:10760296221130061.
54. Azab B, Chainani V, Shah N, McGinn JT. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: A 4-year follow-up study. *Angiology* 2013;64:456-65.
55. Pace NP, Vassallo J. Association between neutrophil-lymphocyte ratio and gestational diabetes-a systematic review and meta-analysis. *J Endocr Soc* 2021;5:bvab051.
56. Adane T, Melku M, Worku YB, Fasil A, Aynalem M, Kelem A, *et al.* The association between neutrophil-to-lymphocyte ratio and glycemic control in type 2 diabetes mellitus: A systematic review and meta-analysis. *J Diabetes Res* 2023;2023:3117396.
57. Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A, *et al.* Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. *J Exp Clin Cancer Res* 2004;23:195-200.
58. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, *et al.* Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. *Cancer Immunol Immunother* 2006;55:684-98.

59. Jain S, Harris J, Ware J. Platelets: Linking hemostasis and cancer. *Arterioscler Thromb Vasc Biol* 2010;30:2362-7.
60. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. *Ann Surg Oncol* 2002;9:287-91.
61. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. *Am J Surg* 2005;189:278-82.
62. Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, et al. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. *Surgery* 2008;143:658-66.
63. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. *Am J Surg* 2009;197:466-72.
64. Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: A systematic review. *Hepatobiliary Pancreat Dis Int* 2014;13:474-81.
65. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte versus platelet-lymphocyte ratio. *Am J Surg* 2010;200:197-203.
66. Garcea G, Cairns V, Berry DP, Neal CP, Metcalfe MS, Dennison AR. Improving the diagnostic yield from staging laparoscopy for periampullary malignancies: The value of preoperative inflammatory markers and radiological tumor size. *Pancreas* 2012;41:233-7.
67. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. *Eur J Cancer* 2011;47:2633-41.
68. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2014;23:1204-12.
69. Colloca G, Venturino A. Peripheral blood cell variables related to systemic inflammation in patients with unresectable or metastatic pancreatic cancer: A systematic review and meta-analysis. *Pancreas* 2021;50:1131-6.
70. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: A meta-analysis. *PLoS One* 2014;9:e101119.
71. Misiewicz A, Dymicka-Piekarska V. Fashionable, but what is their real clinical usefulness? NLR, LMR, and PLR as a promising indicator in colorectal cancer prognosis: A systematic review. *J Inflamm Res* 2023;16:69-81.
72. Guo G, Hu X, Gao T, Zhou H, Li B, Zhou C, et al. Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis. *Front Surg* 2023;10:1139503.
73. Hu Y, Wang S, Ding N, Li N, Huang J, Xiao Z. Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal B-like (HER2(-)) breast cancer. *Clin Breast Cancer* 2020;20:e403-9.
74. Gu X, Gao XS, Cui M, Xie M, Peng C, Bai Y, et al. Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer. *Oncotarget* 2016;7:49878-87.
75. Li DZ, Guo J, Song QK, Hu XJ, Bao XL, Lu J. Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: A systematic review and meta-analysis. *Transl Cancer Res* 2022;11:4037-50.
76. Zhao QT, Yuan Z, Zhang H, Zhang XP, Wang HE, Wang ZK, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. *Int J Cancer* 2016;139:164-70.
77. Zhou H, Li J, Zhang Y, Chen Z, Chen Y, Ye S. Platelet-lymphocyte ratio is a prognostic marker in small cell lung cancer-A systemic review and meta-analysis. *Front Oncol*. 2023;12:1086742. doi:10.3389/fonc.2022.1086742.
78. Jennings LK. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. *Thromb Haemost* 2009;102:248-57.
79. Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets* 2015;26:680-1.
80. Li H, Zhou Y, Ma Y, Han S, Zhou L. The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: A systematic review and meta-analysis. *Kardiol Pol* 2017;75:666-73.
81. Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: A meta-analysis. *Eur J Clin Invest* 2021;51:e13386.
82. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. *J Thromb Thrombolysis* 2012;34:326-34.
83. Sun XP, Li J, Zhu WW, Li DB, Chen H, Li HW, et al. Impact of platelet-to-lymphocyte ratio on clinical outcomes in patients with ST-segment elevation myocardial infarction. *Angiology* 2017;68:346-53.
84. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. *Ann Lab Med* 2019;39:345-57.
85. Fu H, Qin B, Hu Z, Ma N, Yang M, Wei T, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. *Clin Lab* 2015;61:269-73.
86. Wang G, Mivefroshan A, Yaghoobpoor S, Khanzadeh S, Siri G, Rahmani F, et al. Prognostic value of platelet to lymphocyte ratio in sepsis: A systematic review and meta-analysis. *Biomed Res Int* 2022;2022:9056363.
87. Zinellu A, Mangoni AA. A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progression and mortality. *Expert Rev Clin Immunol* 2022;18:1187-202.
88. Ma A, Cheng J, Yang J, Dong M, Liao X, Kang Y. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. *Crit Care* 2020;24:288.
89. Zinellu A, Zinellu E, Mangoni AA, Pau MC, Carru C, Pirina P, et al. Clinical significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute exacerbations of COPD: Present and future. *Eur Respir Rev* 2022;31:220095.
90. Wang Q, Ma J, Jiang Z, Ming L. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: A systematic review and meta-analysis. *Int Angiol* 2018;37:4-11.
91. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res* 2014;20:6212-22.
92. Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: Systemic review and meta-analysis. *Immunotherapy* 2022;14:1481-96.
93. Kou J, Huang J, Li J, Wu Z, Ni L. Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: A systematic review and metaanalysis. *Clin Exp Med* 2023;23:3895-905.
94. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: A meta-analysis. *World J Surg Oncol* 2020;18:197.

95. Mao H, Yang F. Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: A meta-analysis. *Front Oncol* 2023;13:1193962.
96. Zhang B, Xu T. Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: A meta-analysis. *World J Surg Oncol* 2023;21:2.
97. Zhou Y, Dai M, Zhang Z. Prognostic significance of the systemic immune-inflammation index (SII) in patients with small cell lung cancer: A meta-analysis. *Front Oncol* 2022;12:814727.
98. Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: A meta-analysis. *Front Oncol* 2021;11:537140.
99. Peng X, Wang X, Hua L, Yang R. Prognostic and clinical value of the systemic immune-inflammation index in biliary tract cancer: A meta-analysis. *J Immunol Res* 2022;2022:6988489.
100. Li X, Lin H, Ouyang R, Yang Y, Peng J. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: A meta-analysis. *Biosci Rep* 2021;41:BSR20204401.
101. Zeng Z, Xu S, Wang D, Qin G. Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: A meta-analysis. *Syst Rev* 2022;11:247.
102. Jin M, Yuan S, Yuan Y, Yi L. Prognostic and clinicopathological significance of the systemic immune-inflammation index in patients with renal cell carcinoma: A meta-analysis. *Front Oncol* 2021;11:735803.
103. Salazar-Valdivia FE, Valdez-Cornejo VA, Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcón-Braga EA, Mosquera-Rojas MD, et al. Systemic immune-inflammation index and mortality in testicular cancer: A systematic review and meta-analysis. *Diagnostics (Basel)* 2023;13:843.
104. Mulholland M, Jakobsson G, Lei Y, Sundius L, Ljungcrantz I, Rattik S, et al. IL-2R β signalling in lymphocytes promotes systemic inflammation and reduces plasma cholesterol in atherosclerotic mice. *Atherosclerosis* 2021;326:1-10.
105. Kyaw T, Peter K, Li Y, Tipping P, Toh BH, Bobik A. Cytotoxic lymphocytes and atherosclerosis: Significance, mechanisms and therapeutic challenges. *Br J Pharmacol* 2017;174:3956-72.
106. Petrone AB, Eisenman RD, Steele KN, Mosmiller LT, Urhie O, Zdilla MJ. Temporal dynamics of peripheral neutrophil and lymphocytes following acute ischemic stroke. *Neurol Sci* 2019;40:1877-85.
107. Ye Z, Hu T, Wang J, Xiao R, Liao X, Liu M, et al. Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis. *Front Cardiovasc Med* 2022;9:933913.
108. Weng Y, Zeng T, Huang H, Ren J, Wang J, Yang C, et al. Systemic immune-inflammation index predicts 3-month functional outcome in acute ischemic stroke patients treated with intravenous thrombolysis. *Clin Interv Aging* 2021;16:877-86.
109. Liu Y, Ye T, Chen L, Jin T, Sheng Y, Wu G, et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. *Coron Artery Dis* 2021;32:715-20.
110. Huang YW, Yin XS, Li ZP. Association of the systemic immune-inflammation index (SII) and clinical outcomes in patients with stroke: A systematic review and meta-analysis. *Front Immunol* 2022;13:1090305.
111. Mangoni AA, Zinellu A. Systemic inflammation index, disease severity, and mortality in patients with COVID-19: A systematic review and meta-analysis. *Front Immunol* 2023;14:1212998.
112. Jiang D, Bian T, Shen Y, Huang Z. Association between admission systemic immune-inflammation index and mortality in critically ill patients with sepsis: A retrospective cohort study based on MIMIC-IV database. *Clin Exp Med* 2023;23:3641-50.
113. Acar E, Gokcen H, Demir A, Yildirim B. Comparison of inflammation markers with prediction scores in patients with community-acquired pneumonia. *Bratisl Lek Listy* 2021;122:418-23.
114. Zhang D, Wang T, Dong X, Sun L, Wu Q, Liu J, et al. Systemic immune-inflammation index for predicting the prognosis of critically ill patients with acute pancreatitis. *Int J Gen Med* 2021;14:4491-8.
115. Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. *Cancer* 2016;122:2158-67.
116. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. *Br J Cancer* 2013;109:2316-22.
117. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. *Br J Cancer* 2013;108:1677-83.
118. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. *Br J Cancer* 2013;109:416-21.
119. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. *Int J Cancer* 2014;135:362-70.
120. Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: A systematic review and meta-analysis of 38 cohorts. *Dose Response* 2021;19:15593258211064744.
121. Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis. *Medicine (Baltimore)* 2020;99:e23486.
122. Zhang Y, Liu F, Wang Y. Evidence of the prognostic value of pretreatment systemic inflammation response index in cancer patients: A pooled analysis of 19 cohort studies. *Dis Markers* 2020;2020:8854267.
123. Wang L, Qin X, Zhang Y, Xue S, Song X. The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis. *Front Oncol* 2023;13:1006233.
124. Jarmuzek P, Kozłowska K, Defort P, Kot M, Zembron-Lacny A. Prognostic values of systemic inflammatory immunological markers in glioblastoma: A systematic review and meta-analysis. *Cancers (Basel)* 2023;15:3339.
125. Zhang Y, Xing Z, Zhou K, Jiang S. The predictive role of systemic inflammation response index (SIRI) in the prognosis of stroke patients. *Clin Interv Aging* 2021;16:1997-2007.
126. Zhou Y, Zhang Y, Cui M, Zhang Y, Shang X. Prognostic value of the systemic inflammation response index in patients with acute ischemic stroke. *Brain Behav* 2022;12:e2619.
127. Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: A 20-year follow-up cohort study of 42,875 US adults. *J Clin Med* 2023;12:1128.
128. Wang Y, Chen H. A nonlinear relationship between systemic inflammation response index and short-term mortality in patients with acute myocardial infarction: A retrospective study from MIMIC-IV. *Front Cardiovasc Med* 2023;10:1208171.
129. Han K, Shi D, Yang L, Wang Z, Li Y, Gao F, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Ann Med* 2022;54:1667-77.

130. Biyik M, Biyik Z, Asil M, Keskin M. Systemic inflammation response index and systemic immune inflammation index are associated with clinical outcomes in patients with acute pancreatitis? *J Invest Surg* 2022;35:1613-20.
131. Ahn C, Kim W, Lim TH, Cho Y, Choi KS, Jang BH. The delta neutrophil index (DNI) as a prognostic marker for mortality in adults with sepsis: A systematic review and meta-analysis. *Sci Rep* 2018;8:6621.
132. Nigro KG, O'Riordan M, Molloy EJ, Walsh MC, Sandhaus LM. Performance of an automated immature granulocyte count as a predictor of neonatal sepsis. *Am J Clin Pathol* 2005;123:618-24.
133. Nahm CH, Choi JW, Lee J. Delta neutrophil index in automated immature granulocyte counts for assessing disease severity of patients with sepsis. *Ann Clin Lab Sci* 2008;38:241-6.
134. Seok Y, Choi JR, Kim J, Kim YK, Lee J, Song J, *et al.* Delta neutrophil index: A promising diagnostic and prognostic marker for sepsis. *Shock* 2012;37:242-6.
135. Park JH, Byeon HJ, Lee KH, Lee JW, Kronbichler A, Eisenhut M, *et al.* Delta neutrophil index (DNI) as a novel diagnostic and prognostic marker of infection: A systematic review and meta-analysis. *Inflamm Res* 2017;66:863-70.
136. Lee SJ, Park EJ, Lee KJ, Cha YS. The delta neutrophil index is an early predictive marker of severe acute cholecystitis. *Dig Liver Dis* 2019;51:1593-8.
137. Kim TY, Kim SJ, Kim YS, Lee JW, Park EJ, Lee SJ, *et al.* Delta neutrophil index as an early predictive marker of severe acute pancreatitis in the emergency department. *United European Gastroenterol J* 2019;7:488-95.
138. İslam MM, Satici MO, Ademoğlu E, Erdil FN, Odabaşı T, Eker A, *et al.* The role of delta neutrophil index in early identification of severe acute pancreatitis in adult patients: A prospective diagnostic accuracy study. *Med Sci Discov* 2023;7:487-94.
139. Yankov YG. Delta neutrophil index as a new marker of purulent inflammation in men with non-odontogenic abscesses of the neck. *Cureus* 2023;15:e47165.
140. Shin IS, Gong SC, An S, Kim K. Delta neutrophil index as a prognostic factor for mortality in patients with Fournier's gangrene. *Int J Urol* 2022;29:1287-93.